{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:53:30Z","timestamp":1793224410810,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The National Key Research and Development Program of China","award":["2022YFC2705103"],"award-info":[{"award-number":["2022YFC2705103"]}]},{"name":"The National Key Research and Development Program of China","award":["2022YFC2705100"],"award-info":[{"award-number":["2022YFC2705100"]}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LTGD24H050002"],"award-info":[{"award-number":["LTGD24H050002"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Medicine &Health Technology Project of Zhejiang Province","award":["2024646275"],"award-info":[{"award-number":["2024646275"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00467-025-06769-3","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T09:23:52Z","timestamp":1744363432000},"page":"2561-2569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Telitacicept as a BAFF\/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis"],"prefix":"10.1007","volume":"40","author":[{"given":"Yanyan","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiqin","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9459-3078","authenticated-orcid":false,"given":"Haidong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"6769_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41584-021-00718-8","volume":"18","author":"RA Watts","year":"2022","unstructured":"Watts RA, Hatemi G, Burns JC, Mohammad AJ (2022) Global epidemiology of vasculitis. Nat Rev Rheumatol 18:22\u201334. https:\/\/doi.org\/10.1038\/s41584-021-00718-8","journal-title":"Nat Rev Rheumatol"},{"key":"6769_CR2","doi-asserted-by":"publisher","unstructured":"Jin Y, He X, Lin W, Peng Z, Li W, Xiang W, Chen Z, Fu H, Mao J (2014) Serum cytokine profiles in children with IgA vasculitis with nephritis. Biomol Biomed. https:\/\/doi.org\/10.17305\/bb.2024.11081","DOI":"10.17305\/bb.2024.11081"},{"key":"6769_CR3","doi-asserted-by":"publisher","first-page":"7538","DOI":"10.3390\/ijms22147538","volume":"22","author":"H Sugino","year":"2021","unstructured":"Sugino H, Sawada Y, Nakamura M (2021) IgA vasculitis: etiology, treatment, biomarkers and epigenetic changes. Int J Mol Sci 22:7538. https:\/\/doi.org\/10.3390\/ijms22147538","journal-title":"Int J Mol Sci"},{"key":"6769_CR4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/S0140-6736(02)09835-5","volume":"360","author":"J Ronkainen","year":"2002","unstructured":"Ronkainen J, Nuutinen M, Koskimies O (2002) The adult kidney 24 years after childhood Henoch-Sch\u00f6nlein purpura: a retrospective cohort study. Lancet 360:666\u2013670. https:\/\/doi.org\/10.1016\/S0140-6736(02)09835-5","journal-title":"Lancet"},{"key":"6769_CR5","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1053\/j.ajkd.2006.02.178","volume":"47","author":"R Coppo","year":"2006","unstructured":"Coppo R, Andrulli S, Amore A, Gianoglio B et al (2006) Predictors of outcome in Henoch-Sch\u00f6nlein nephritis in children and adults. Am J Kidney Dis 47:993\u20131003. https:\/\/doi.org\/10.1053\/j.ajkd.2006.02.178","journal-title":"Am J Kidney Dis"},{"key":"6769_CR6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100:S1-1S276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"key":"6769_CR7","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/rheumatology\/kez041","volume":"58","author":"S Ozen","year":"2019","unstructured":"Ozen S, Marks SD, Brogan P, Groot N et al (2019) European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology (Oxford) 58:1607\u20131616. https:\/\/doi.org\/10.1093\/rheumatology\/kez041","journal-title":"Rheumatology (Oxford)"},{"key":"6769_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00467-024-06502-6","volume":"40","author":"M Vivarelli","year":"2025","unstructured":"Vivarelli M, Samuel S, Coppo R, Barratt J et al (2025) IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis. Pediatr Nephrol 40:533\u2013569. https:\/\/doi.org\/10.1007\/s00467-024-06502-6","journal-title":"Pediatr Nephrol"},{"key":"6769_CR9","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105:S117-117S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"6769_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ki.2010.150","volume":"78","author":"E Pillebout","year":"2010","unstructured":"Pillebout E, Alberti C, Guillevin L, Ouslimani A et al (2010) Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Sch\u00f6nlein Purpura. Kidney Int 78:495\u2013502. https:\/\/doi.org\/10.1038\/ki.2010.150","journal-title":"Kidney Int"},{"key":"6769_CR11","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00467-019-04238-2","volume":"34","author":"M Koskela","year":"2019","unstructured":"Koskela M, Jahnukainen T, End\u00e9n K, Arikoski P et al (2019) Methylprednisolone or cyclosporine a in the treatment of Henoch-Sch\u00f6nlein nephritis: a nationwide study. Pediatr Nephrol 34:1447\u20131456. https:\/\/doi.org\/10.1007\/s00467-019-04238-2","journal-title":"Pediatr Nephrol"},{"key":"6769_CR12","doi-asserted-by":"publisher","first-page":"sfae15","DOI":"10.1093\/ckj\/sfae115","volume":"17","author":"Y Gan","year":"2024","unstructured":"Gan Y, Chen J, Wang M, Li Q et al (2024) The efficacy and safety of tacrolimus in treating refractory IgA vasculitis nephritis: a single-center retrospective study on 16 cases. Clin Kidney J 17:sfae15. https:\/\/doi.org\/10.1093\/ckj\/sfae115","journal-title":"Clin Kidney J"},{"key":"6769_CR13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00467-017-3846-6","volume":"33","author":"A Hackl","year":"2018","unstructured":"Hackl A, Becker JU, K\u00f6rner LM, Ehren R et al (2018) Mycophenolate mofetil following glucocorticoid treatment in Henoch-Sch\u00f6nlein purpura nephritis: the role of early initiation and therapeutic drug monitoring. Pediatr Nephrol 33:619\u2013629. https:\/\/doi.org\/10.1007\/s00467-017-3846-6","journal-title":"Pediatr Nephrol"},{"key":"6769_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00296-002-0208-9","volume":"22","author":"S Singh","year":"2002","unstructured":"Singh S, Devidayal KL, Joshi K et al (2002) Severe Henoch-Sch\u00f6nlein nephritis: resolution with azathioprine and steroids. Rheumatol Int 22:133\u2013137. https:\/\/doi.org\/10.1007\/s00296-002-0208-9","journal-title":"Rheumatol Int"},{"key":"6769_CR15","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1093\/ndt\/gfz151","volume":"35","author":"X Zhang","year":"2020","unstructured":"Zhang X, Xie X, Shi S, Liu L et al (2020) Plasma galactose-deficient immunoglobulin A1 and loss of kidney function in patients with immunoglobulin A vasculitis nephritis. Nephrol Dial Transplant 35:2117\u20132123. https:\/\/doi.org\/10.1093\/ndt\/gfz151","journal-title":"Nephrol Dial Transplant"},{"key":"6769_CR16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1042\/cs0830281","volume":"83","author":"DJ O'Donoghue","year":"1992","unstructured":"O\u2019Donoghue DJ, Jewkes F, Postlethwaite RJ, Ballardie FW (1992) Autoimmunity to glomerular antigens in Henoch-Schoenlein nephritis. Clin Sci (Lond) 83:281\u2013287. https:\/\/doi.org\/10.1042\/cs0830281","journal-title":"Clin Sci (Lond)"},{"key":"6769_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41581-018-0074-7","volume":"15","author":"K Oleinika","year":"2019","unstructured":"Oleinika K, Mauri C, Salama AD (2019) Effector and regulatory B cells in immune-mediated kidney disease. Nat Rev Nephrol 15:11\u201326. https:\/\/doi.org\/10.1038\/s41581-018-0074-7","journal-title":"Nat Rev Nephrol"},{"key":"6769_CR18","doi-asserted-by":"publisher","first-page":"11510","DOI":"10.1038\/s41598-021-91055-z","volume":"11","author":"D Prieto-Pe\u00f1a","year":"2021","unstructured":"Prieto-Pe\u00f1a D, Genre F, Remuzgo-Mart\u00ednez S, Pulito-Cueto V et al (2021) BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis. Sci Rep 11:11510. https:\/\/doi.org\/10.1038\/s41598-021-91055-z","journal-title":"Sci Rep"},{"issue":"Suppl 124","key":"6769_CR19","first-page":"195","volume":"38","author":"R Fenoglio","year":"2020","unstructured":"Fenoglio R, Sciascia S, Naretto C, De Simone E et al (2020) Rituximab in severe immunoglobulin-A vasculitis (Henoch-Sch\u00f6nlein) with aggressive nephritis. Clin Exp Rheumatol 38(Suppl 124):195\u2013200","journal-title":"Clin Exp Rheumatol"},{"key":"6769_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12969-018-0285-2","volume":"16","author":"CB Crayne","year":"2018","unstructured":"Crayne CB, Eloseily E, Mannion ML, Azerf SP et al (2018) Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature. Pediatr Rheumatol Online J 16:71. https:\/\/doi.org\/10.1186\/s12969-018-0285-2","journal-title":"Pediatr Rheumatol Online J"},{"key":"6769_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jpeds.2008.12.049","volume":"155","author":"KJ Donnithorne","year":"2009","unstructured":"Donnithorne KJ, Atkinson TP, Hinze CH, Nogueira JB et al (2009) Rituximab therapy for severe refractory chronic Henoch-Sch\u00f6nlein purpura. J Pediatr 155:136\u2013139. https:\/\/doi.org\/10.1016\/j.jpeds.2008.12.049","journal-title":"J Pediatr"},{"key":"6769_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","volume":"21","author":"F Mackay","year":"2003","unstructured":"Mackay F, Schneider P, Rennert P, Browning J (2003) BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 21:231\u2013264. https:\/\/doi.org\/10.1146\/annurev.immunol.21.120601.141152","journal-title":"Annu Rev Immunol"},{"key":"6769_CR23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D, Merrill JT et al (2024) Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 83:475\u2013487. https:\/\/doi.org\/10.1136\/ard-2023-224854","journal-title":"Ann Rheum Dis"},{"key":"6769_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae601","author":"H Gao","year":"2024","unstructured":"Gao H, Lin J, Yang M, Gui M et al (2024) Telitacicept add-on therapy in refractory idiopathic inflammatory myopathy: insights from a pilot study. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/keae601","journal-title":"Rheumatology (Oxford)"},{"key":"6769_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000540326","volume":"149","author":"L Liu","year":"2024","unstructured":"Liu L, Liu Y, Li J, Tang C et al (2024) Efficacy and safety of telitacicept in IgA nephropathy: a retrospective, multicenter study. Nephron 149:1\u201310. https:\/\/doi.org\/10.1159\/000540326","journal-title":"Nephron"},{"key":"6769_CR26","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","volume":"8","author":"J Lv","year":"2023","unstructured":"Lv J, Liu L, Hao C, Li G et al (2023) Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep 8:499\u2013506. https:\/\/doi.org\/10.1016\/j.ekir.2022.12.014","journal-title":"Kidney Int Rep"},{"key":"6769_CR27","doi-asserted-by":"publisher","first-page":"1268929","DOI":"10.3389\/fimmu.2023.1268929","volume":"14","author":"L Zhang","year":"2023","unstructured":"Zhang L, Jin H, Wang D, Wang Y (2023) Case report: successful treatment of refractory membranous nephropathy with telitacicept. Front Immunol 14:1268929. https:\/\/doi.org\/10.3389\/fimmu.2023.1268929","journal-title":"Front Immunol"},{"key":"6769_CR28","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S (2021) Telitacicept: first approval. Drugs 81:1671\u20131675. https:\/\/doi.org\/10.1007\/s40265-021-01591-1","journal-title":"Drugs"},{"key":"6769_CR29","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","volume":"43","author":"F Shi","year":"2021","unstructured":"Shi F, Xue R, Zhou X, Shen P et al (2021) Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol 43:666\u2013673. https:\/\/doi.org\/10.1080\/08923973.2021.1973493","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"6769_CR30","doi-asserted-by":"publisher","first-page":"sfae85","DOI":"10.1093\/ckj\/sfae285","volume":"17","author":"M Wang","year":"2024","unstructured":"Wang M, Ma J, Yao L, Fan Y (2024) Efficacy and safety of telitacicept, a BLyS\/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case-control study. Clin Kidney J 17:sfae85. https:\/\/doi.org\/10.1093\/ckj\/sfae285","journal-title":"Clin Kidney J"},{"key":"6769_CR31","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrneph.2014.126","volume":"10","author":"JC Davin","year":"2014","unstructured":"Davin JC, Coppo R (2014) Henoch-Sch\u00f6nlein purpura nephritis in children. Nat Rev Nephrol 10:563\u2013573. https:\/\/doi.org\/10.1038\/nrneph.2014.126","journal-title":"Nat Rev Nephrol"},{"key":"6769_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223218","volume":"14","author":"D Shi","year":"2019","unstructured":"Shi D, Chan H, Yang X, Zhang G et al (2019) Risk factors associated with IgA vasculitis with nephritis (Henoch-Sch\u00f6nlein purpura nephritis) progressing to unfavorable outcomes: a meta-analysis. PLoS One 14:e0223218. https:\/\/doi.org\/10.1371\/journal.pone.0223218","journal-title":"PLoS ONE"},{"key":"6769_CR33","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.autrev.2017.10.009","volume":"16","author":"MH Heineke","year":"2017","unstructured":"Heineke MH, Ballering AV, Jamin A, Ben Mkaddem S et al (2017) New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Sch\u00f6nlein purpura). Autoimmun Rev 16:1246\u20131253. https:\/\/doi.org\/10.1016\/j.autrev.2017.10.009","journal-title":"Autoimmun Rev"},{"key":"6769_CR34","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1681\/ASN.2016060640","volume":"28","author":"RA Lafayette","year":"2017","unstructured":"Lafayette RA, Canetta PA, Rovin BH, Appel GB et al (2017) A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol 28:1306\u20131313. https:\/\/doi.org\/10.1681\/ASN.2016060640","journal-title":"J Am Soc Nephrol"},{"key":"6769_CR35","doi-asserted-by":"publisher","first-page":"1423035","DOI":"10.3389\/fimmu.2024.1423035","volume":"15","author":"C Fan","year":"2024","unstructured":"Fan C, Yang T, Zheng S, Liao X et al (2024) Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: a real-life, single-center observational study. Front Immunol 15:1423035. https:\/\/doi.org\/10.3389\/fimmu.2024.1423035","journal-title":"Front Immunol"},{"key":"6769_CR36","doi-asserted-by":"publisher","first-page":"1298650","DOI":"10.3389\/fimmu.2023.1298650","volume":"14","author":"L Huang","year":"2023","unstructured":"Huang L, Lin W, Liu Y, Zhu J et al (2023) Combination treatment with telitacicept, cyclophosphamide and glucocorticoids for severe Granulomatous polyangiitis: a case report and literature review. Front Immunol 14:1298650. https:\/\/doi.org\/10.3389\/fimmu.2023.1298650","journal-title":"Front Immunol"},{"key":"6769_CR37","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.ekir.2024.01.003","volume":"9","author":"J Zan","year":"2024","unstructured":"Zan J, Liu L, Li G, Zheng H et al (2024) Effect of telitacicept on circulating Gd-IgA1 and IgA-containing immune complexes in IgA nephropathy. Kidney Int Rep 9:1067\u20131071. https:\/\/doi.org\/10.1016\/j.ekir.2024.01.003","journal-title":"Kidney Int Rep"},{"key":"6769_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.515","volume":"5","author":"L Ji","year":"2020","unstructured":"Ji L, Geng Y, Zhang X, Deng X et al (2020) (2024) B cell pathway dual inhibition for systemic lupus erythematosus: a prospective single-arm cohort study of telitacicept. MedComm 5:e515. https:\/\/doi.org\/10.1002\/mco2.515","journal-title":"MedComm"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06769-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-06769-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06769-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T05:56:50Z","timestamp":1750831010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-06769-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6769"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-06769-3","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been ethically reviewed and approved by the Ethics Committee of Children\u2019s Hospital, Zhejiang University School of Medicine, as indicated by the approval number (2024-IRB- 0263-P- 01). In line with ethical standards, informed consent has been secured from the guardians of the participating children.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}